**AstraZeneca Reports Strong Financial Performance for Full Year and Q4 2025**
AstraZeneca announced robust financial results for the full year and fourth quarter of 2025, driven primarily by increased sales of its cancer medications. The company highlighted growth in earnings supported by successful product launches and expansion into new markets worldwide. Looking ahead, AstraZeneca projects continued revenue growth in 2026, underpinned …